-
Mashup Score: 10Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy - 10 day(s) ago
Abstract. Purpose: Accumulating toxicities hinder indefinite chemotherapy for many patients with metastatic/recurrent HER2-negative breast cancer. We conducted a phase II trial of pembrolizumab monotherapy following induction chemotherapy to determine the efficacy of maintenance immunotherapy in patients with metastatic HER2-negative inflammatory breast cancer (IBC) and non-IBC triple-negative breast cancer (TNBC) and a biomarker study. Patients and Methods: Patients with a complete response (CR), partial response (PR), or stable disease (SD) after at least 3 cycles of chemotherapy for HER2-negative breast cancer received pembrolizumab, regardless of programmed death-ligand 1 expression. Pembrolizumab (200 mg) was administered every 3 weeks until disease progression, intolerable toxicity, or 2 years of pembrolizumab exposure. The endpoints included the 4-month disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and response biomarkers in the blood. Resul
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3UH biomedical research grants pumps millions into state economy | University of Hawaiʻi System News - 16 day(s) ago
UH brought in $58 million in federal biomedical research grants to the state in fiscal year 2023.
Source: www.hawaii.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Free skin cancer checks goes on the road around Oʻahu | University of Hawaiʻi System News - 18 day(s) ago
The new Skin ✓ Van is the first of its kind in Hawaiʻi and will make its debut on April 20.
Source: www.hawaii.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41
No longer FDA-approved accelerated approvals (AAs) for malignant hematology and oncology indications
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Hawaiʻi benefits from UH Mānoa being a national leader in federal health funding | University of Hawaiʻi System News - 1 month(s) ago
UH Mānoa received $57.8 million in 2023, placing at 130 out of 2,886 other entities that received NIH funding.
Source: www.hawaii.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0AACI Leadership Diversity and Development Workshop | Association of American Cancer Institutes - 2 month(s) ago
The Leadership Diversity and Development Workshop is one component of the Leadership Diversity and Development Initiative (LDDI), the presidential initiative of Dr. Caryn Lerman, of USC Norris Comprehensive Cancer Center.
Source: www.aaci-cancer.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
His groundbreaking research, which he performed with Yvonne Barr, his doctoral student, uncovered the first virus capable of causing cancer in humans.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Leading UH Mānoa to become a Native Hawaiian place of learning | University of Hawaiʻi System News - 2 month(s) ago
A total of 13 units comprise the first cohort of UH Mānoa units that will engage in an initial two-year process.
Source: www.hawaii.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Your 2024 Guide to Covid Symptoms and Treatment - 2 month(s) ago
Rest, fluids and medications are your friends.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Cancers - 2 month(s) ago
Cancers, an international, peer-reviewed Open Access journal.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
Congratulations to Dr. T Iwase and Dr. J Reubenʻs team for successfully showing that pembrolizumab is potentially a maintenance therapy for those with T-cell clonality in the blood of metastatic breast cancer of IBC and triple-negative breast cancer. https://t.co/pQDZlJe61A